Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ/CatenaŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera has a late-stage development pipeline in orphan indications. The lead compound RaxoneŽ/CatenaŽ (INN: idebenone) is being developed in three indications: Leber's Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy, and Primary Progressive Multiple Sclerosis.

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ/CatenaŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being initiated to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.

Latest News

April 14, 2015
Santhera Reports 2014 Financial Results and Significant Progress in All Programs
---
April 09, 2015
Santhera receives FDA Fast Track Designation for RaxoneŽ/CatenaŽ (idebenone) for theTreatment of Duchenne Muscular Dystrophy
---
March 11, 2015
Principal Investigator to Present Phase III Data on Idebenone in Duchenne Muscular Dystrophy (DMD) at the Annual Meeting of the American Academy of Neurology (AAN)